{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T12:40:30Z","timestamp":1792586430933,"version":"4.5.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"DOI":"10.1007\/s12282-026-01925-5","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T11:48:43Z","timestamp":1792583323000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A phase II study combining radiotherapy and atezolizumab\/nab-paclitaxel for inoperable or recurrent programmed death-ligand 1-positive triple-negative breast cancer: IMRad-Br study protocol and safety run-in"],"prefix":"10.1007","author":[{"given":"Hiroshi","family":"Ishiguro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Hoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-ei","family":"Noda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emi","family":"Tokuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asami","family":"Nukui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Yoshimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiaki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigehira","family":"Saji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Ohtake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Osaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8786-9080","authenticated-orcid":false,"given":"Yoshiyuki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"issue":"2","key":"1925_CR1","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s12282-022-01423-4","volume":"30","author":"K Tada","year":"2023","unstructured":"Tada K, Kumamaru H, Miyata H, Asaga S, Iijima K, Ogo E, et al. Characteristics of female breast cancer in Japan: annual report of the National Clinical Database in 2018. Breast Cancer. 2023;30(2):157\u201366.","journal-title":"Breast Cancer"},{"issue":"2","key":"1925_CR2","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s12282-024-01545-x","volume":"31","author":"T Iwamoto","year":"2004","unstructured":"Iwamoto T, Kumamaru H, Niikura N, Sagara Y, Miyashita M, Konishi T, et al. Survival trends and patient characteristics between 2004 and 2016 for breast cancer in Japan based on the National Clinical Database-Breast Cancer Registry. Breast Cancer (Auckl). 2004;31(2):185\u201394.","journal-title":"Breast Cancer (Auckl)"},{"issue":"22","key":"1925_CR3","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108\u201321.","journal-title":"N Engl J Med"},{"issue":"10265","key":"1925_CR4","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","volume":"396","author":"J Cortes","year":"2020","unstructured":"Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396(10265):1817\u201328.","journal-title":"Lancet"},{"issue":"8","key":"1925_CR5","doi-asserted-by":"publisher","first-page":"5108","DOI":"10.21037\/tcr.2020.02.54","volume":"9","author":"M Yoshimura","year":"2020","unstructured":"Yoshimura M. Radiation therapy for primary tumor of de novo stage IV breast cancer. Transl Cancer Res. 2020;9(8):5108\u201316.","journal-title":"Transl Cancer Res"},{"issue":"20","key":"1925_CR6","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919\u201329.","journal-title":"N Engl J Med"},{"issue":"10445","key":"1925_CR7","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1016\/S0140-6736(24)00594-4","volume":"403","author":"X Liu","year":"2024","unstructured":"Liu X, Zhang Y, Yang KY, Zhang N, Jin F, Zou GR, et al. Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet. 2024;403(10445):2720\u201331.","journal-title":"Lancet"},{"issue":"10434","key":"1925_CR8","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(24)00317-9","volume":"403","author":"D Lorusso","year":"2024","unstructured":"Lorusso D, Xiang Y, Hasegawa K, Scambia G, Leiva M, Ramos-Elias P, et al. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial. Lancet. 2024;403(10434):1341\u201350.","journal-title":"Lancet"},{"issue":"3","key":"1925_CR9","doi-asserted-by":"publisher","first-page":"319","DOI":"10.5230\/jgc.2021.21.e24","volume":"21","author":"M Muto","year":"2021","unstructured":"Muto M, Nakata H, Ishigaki K, Tachibana S, Yoshida M, Muto M, et al. Successful treatment of advanced gastric cancer with brain metastases through an abscopal effect by radiation and immune checkpoint inhibitor therapy. J Gastric Cancer. 2021;21(3):319\u201324.","journal-title":"J Gastric Cancer"},{"issue":"1","key":"1925_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-27048-3","volume":"12","author":"M Takada","year":"2022","unstructured":"Takada M, Yoshimura M, Kotake T, Kawaguchi K, Uozumi R, Kataoka M, et al. Phase Ib\/II study of nivolumab combined with palliative radiation therapy for bone metastasis in patients with HER2-negative metastatic breast cancer. Sci Rep. 2022;12(1):22397.","journal-title":"Sci Rep"},{"key":"1925_CR11","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1038\/s41591-018-0232-2","volume":"24","author":"SC Formenti","year":"2018","unstructured":"Formenti SC, Rudqvist NP, Golden E, Cooper B, Wennerberg E, Lhuillier C, et al. Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat Med. 2018;24:1845\u201351. https:\/\/doi.org\/10.1038\/s41591-018-0232-2.","journal-title":"Nat Med"},{"issue":"1","key":"1925_CR12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s43856-023-00343-4","volume":"3","author":"K Mimura","year":"2023","unstructured":"Mimura K, Ogata T, Yoshimoto Y, Yoshida D, Nakajima S, Sato H, et al. Phase I\/II clinical trial of nivolumab in combination with oligo-fractionated irradiation for unresectable advanced or recurrent gastric cancer. Commun Med (Lond). 2023;3(1):111.","journal-title":"Commun Med (Lond)"},{"key":"1925_CR13","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.radonc.2020.07.035","volume":"151","author":"CM Sha","year":"2020","unstructured":"Sha CM, Lehrer EJ, Hwang C, Trifiletti DM, Mackley HB, Drabick JJ, et al. Toxicity in combination immune checkpoint inhibitor and radiation therapy: a systematic review and meta-analysis. Radiother Oncol. 2020;151:141\u20138.","journal-title":"Radiother Oncol"},{"issue":"2","key":"1925_CR14","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1001\/jamaoncol.2021.6439","volume":"8","author":"MS Anscher","year":"2022","unstructured":"Anscher MS, Arora S, Weinstock C, Amatya A, Bandaru P, Tang C, et al. Association of radiation therapy with risk of adverse events in patients receiving immunotherapy: a pooled analysis of trials in the US Food and Drug Administration Database. JAMA Oncol. 2022;8(2):232\u201340.","journal-title":"JAMA Oncol"},{"issue":"3","key":"1925_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2023.101384","volume":"9","author":"T Tison","year":"2024","unstructured":"Tison T, Loap P, Arnaud E, Cao K, Bringer S, Kissel M, et al. Tolerance of concurrent adjuvant radiation therapy and pembrolizumab for triple negative breast cancer: real life experience. Adv Radiat Oncol. 2024;9(3):101384.","journal-title":"Adv Radiat Oncol"},{"key":"1925_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15618","volume":"8","author":"C Vanpouille-Box","year":"2017","unstructured":"Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ, et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun. 2017;8:15618. https:\/\/doi.org\/10.1038\/ncomms15618.","journal-title":"Nat Commun"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01925-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-026-01925-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01925-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T11:48:44Z","timestamp":1792583324000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-026-01925-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,21]]},"references-count":16,"alternative-id":["1925"],"URL":"https:\/\/doi.org\/10.1007\/s12282-026-01925-5","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,21]]},"assertion":[{"value":"2 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H. Ishiguro received research grants from Eisai, Daiichi Sankyo, Chugai, Takeda, Astra Zeneca, MSD, Ono, Nipro, and consulting fees from Mitsubishi Tanabe Pharma Corporation, Astra Zeneca, Asahi Kasei, and payments from Eisai, Chugai, Pfizer, Kyowa Kirin, Daiichi Sankyo, Taiho, Astra Zeneca, MSD, and Eli Lilly. Y. Yoshimoto received research grants from Chugai, and payments from Radiation Therapy Asunaro Meeting, and reports funding for an endowed chair at the Okinawa PCR-Rinsyo Center. S. Saji received research grants from Bristol-Myers Squibb, Eli Lilly, Chugai, Gilead, MSD, Astra Zeneca, Daiichi Sankyo, Pfizer, and payment from Chugai, Kyowa Kirin, MSD, Guardant Health, Eisai, Takeda, Daiichi Sankyo, Eli Lilly, Astra Zeneca, Pfizer, Taiho, Ono, Myriad, Gilead, Exact Sciences, and Nipro. He is an advisory board member of Chugai\/Roche, Astra Zeneca, Eli Lilly, Pfizer, Ono, Daiichi Sankyo, and MSD and an executive board member of JBCRG, JBCS and JSMO. T. Ohtake received research grants from Nippon-Kayaku, Asahi Kasei, Taiho, and payment from Chugai, Astra Zeneca, Pfizer, Eisai, Daiichi Sankyo, Eli Lilly, Exact Sciences, MSD, Nipro, Takeda, and Kyowa Kirin. A. Osaki received research grants from Astra Zeneca, Eisai, MSD, Daiichi Sankyo, Chugai, Novartis, Eli Lilly, Pfizer, Takeda, Ono, Nipro, Incyte Biosciences, and payments from Eisai, Kyowa Kirin, Daiichi Sankyo, Chugai, and Eli Lilly. Y. Suzuki received research grants from Jusendo General Hospital and Chugai, and payment from Brainlab, Ono, Astra Zeneca, and Varian Medical Systems. The other authors have no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}